CytomX Therapeutics (CTMX) announced that it achieved a clinical candidate milestone under its t-cell engaging biospecific, TCB, agreement with Astellas (ALPMY). The clinical candidate is the first Probody TCB molecule to progress in the collaboration and will trigger a $5M dollar milestone payment to CytomX. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets."The progress with Astellas highlights our strategy to create value through a broad, diversified pipeline of wholly-owned and partnered therapeutic programs as well as expanding our research and development efforts in the field of TCBs. T-cell engaging therapies hold tremendous promise; however, the potency of this modality can lead to widespread activation of the immune system and a narrow therapeutic window. Localizing T-cell activity to the tumor microenvironment could result in important breakthroughs for patients, and the Probody platform has potential to address this challenge," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
- Biotech Alert: Searches spiking for these stocks today
- CTMX Surges after Announcing MRNA Collaboration
- CytomX Therapeutics to host conference call